Journal
HIV CLINICAL TRIALS
Volume 14, Issue 2, Pages 75-79Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1310/hct1402-75
Keywords
anal infection; anal intraepithelial neoplasia; HIV-1 infection; human papillomavirus; male
Categories
Funding
- Merck
- Qiagen
- Weill-Cornell Clinical and Translational Science Center (CTSC)) [K23 AI 55038, UL1 RR024996]
- UCLA CTSC [U01 CAl21947-01, M01 RR00865]
- UCSF Clinical and Translational Science Institute [UL1 RR024131]
Ask authors/readers for more resources
Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available